JOE Society for Endocrinology Archive
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Journal of Endocrinology (2002) 174, 353-359       DOI: 10.1677/joe.0.1740353
© 2002 Society for Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (13)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Uemura, H
Right arrow Articles by Irahara, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Uemura, H
Right arrow Articles by Irahara, M
Journal of Endocrinology, Vol 174, Issue 2, 353-359
Copyright © 2002 by Society for Endocrinology


Articles

Serum osteoprotegerin/osteoclastogenesis-inhibitory factor during pregnancy and lactation and the relationship with calcium-regulating hormones and bone turnover markers

H Uemura, T Yasui, M Kiyokawa, A Kuwahara, H Ikawa, T Matsuzaki, M Maegawa, H Furumoto, and M Irahara


Pregnancy and lactation induce dynamic changes in maternal bone and calcium metabolism. A novel cytokine termed osteoprotegerin (OPG)/osteoclastogenesis-inhibitory factor (OCIF) was recently isolated; this cytokine inhibits osteoclast maturation. To define the effects of pregnancy and lactation on circulating OPG/OCIF in mothers, we studied the changes in the levels of OPG/ OCIF as well as those of calcium-regulating hormones and biochemical markers of bone turnover in the maternal circulation during pregnancy (at 8-11 weeks, at 22-30 weeks, at 35-36 weeks and immediately before delivery) and lactation (at 4 days and at 1 month postpartum). Serum intact parathyroid hormone levels did not change and were almost within the normal range in this period. In contrast, serum 1,25-dihydroxyvitamin D levels increased with gestational age and were above the normal range during pregnancy. After delivery, they fell rapidly and significantly (P<0.01) to the normal range. The levels of serum bone-specific alkaline phosphatase, one of the markers of bone formation, increased with gestational age. After delivery, these levels were further increased at 1 month postpartum. The levels at 1 month postpartum were significantly higher than those at 8-11 and 22-30 weeks of pregnancy (P<0.01 and P<0.05 respectively). The levels of serum C-terminal telopeptides of type I collagen, one of the markers of bone resorption, did not change during pregnancy. After delivery, they rapidly and significantly (P<0.01) rose at 4 days postpartum, and had then fallen by 1 month postpartum. Circulating OPG/OCIF levels gradually increased with gestational age and significantly (P<0.01) increased immediately before delivery to 1.40+/-0.53 ng/ml (means+/-S.D.) compared with those in the non-pregnant, non-lactating controls (0.58+/-0.11 ng/ml). After delivery, they fell rapidly to 0.87+/-0.27 ng/ml at 4 days postpartum and had fallen further by 1 month postpartum. These results suggest that the fall in OPG/OCIF levels may be partially connected with the marked acceleration of bone resorption after delivery.


This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
D. Vega, N. M. Maalouf, and K. Sakhaee
The Role of Receptor Activator of Nuclear Factor-{kappa}B (RANK)/RANK Ligand/Osteoprotegerin: Clinical Implications
J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4514 - 4521.
[Abstract] [Full Text] [PDF]


Home page
IBMS BoneKEyHome page
J. J. Wysolmerski
Conversations Between Breast and Bone: Physiological Bone Loss During Lactation as Evolutionary Template for Osteolysis in Breast Cancer and Pathological Bone Loss After Menopause
IBMS BoneKEy, August 1, 2007; 4(8): 209 - 225.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
L. Ardeshirpour, P. Dann, D. J. Adams, T. Nelson, J. VanHouten, M. C. Horowitz, and J. J. Wysolmerski
Weaning Triggers a Decrease in Receptor Activator of Nuclear Factor-{kappa}B Ligand Expression, Widespread Osteoclast Apoptosis, and Rapid Recovery of Bone Mass after Lactation in Mice
Endocrinology, August 1, 2007; 148(8): 3875 - 3886.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
P. F. Perez, J. Dore, M. Leclerc, F. Levenez, J. Benyacoub, P. Serrant, I. Segura-Roggero, E. J. Schiffrin, and A. Donnet-Hughes
Bacterial Imprinting of the Neonatal Immune System: Lessons From Maternal Cells?
Pediatrics, March 1, 2007; 119(3): e724 - e732.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Rogers and R. Eastell
Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor {kappa}B Ligand: Clinical Utility in Metabolic Bone Disease Assessment
J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6323 - 6331.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
J. N. VanHouten and J. J. Wysolmerski
Low Estrogen and High Parathyroid Hormone-Related Peptide Levels Contribute to Accelerated Bone Resorption and Bone Loss in Lactating Mice
Endocrinology, December 1, 2003; 144(12): 5521 - 5529.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K. E. Naylor, A. Rogers, R. B. Fraser, V. Hall, R. Eastell, and A. Blumsohn
Serum Osteoprotegerin as a Determinant of Bone Metabolism in a Longitudinal Study of Human Pregnancy and Lactation
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5361 - 5365.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the Society for Endocrinology.